Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $28.70

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $28.70.

A number of equities analysts have recently commented on FDMT shares. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Royal Bank Of Canada increased their target price on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, November 11th. Barclays reduced their price target on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Finally, Chardan Capital reiterated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, December 18th.

4D Molecular Therapeutics Trading Down 9.3%

Shares of 4D Molecular Therapeutics stock opened at $7.90 on Wednesday. The company has a market cap of $451.33 million, a PE ratio of -2.11 and a beta of 2.96. The company has a 50 day moving average of $10.62 and a 200-day moving average of $7.61. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.01. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. Research analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 2,678 shares of the company’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the completion of the transaction, the insider directly owned 3,594 shares in the company, valued at approximately $43,128. This represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 10,380 shares of company stock worth $111,357 over the last quarter. Insiders own 9.60% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC grew its holdings in shares of 4D Molecular Therapeutics by 1,103.4% during the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock worth $1,290,000 after purchasing an additional 367,317 shares during the last quarter. Invesco Ltd. boosted its position in 4D Molecular Therapeutics by 318.3% during the 1st quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock worth $380,000 after buying an additional 89,611 shares during the period. Russell Investments Group Ltd. acquired a new stake in 4D Molecular Therapeutics during the 1st quarter worth approximately $63,000. Nuveen LLC bought a new stake in 4D Molecular Therapeutics during the 1st quarter worth approximately $486,000. Finally, Kera Capital Partners Inc. acquired a new position in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $89,000. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.